Karin Holmsten

Publications
CV
Public outreach and news

Articles

Article: CLINICAL GENITOURINARY CANCER. 2023;21(6):e438-e448
Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
Holmsten K; Eknert J; Ofverholm E; Papantoniou D; Jawdat F; Verbiene I; Laurell A; Janes E; Sandzen J; Wojtyna-Dziedzic E; Lagstam I; Soderkvist K; Svedman FC; Liedberg F; Bruzelius M; Fransson A-S; Kjellstrom S; Omland LH; Pappot H; Ullen A
Article: EUROPEAN UROLOGY. 2022;81(5):523-532
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
Sjodahl G; Abrahamsson J; Holmsten K; Bernardo C; Chebil G; Eriksson P; Johansson I; Kollberg P; Lindh C; Lovgren K; Marzouka N-A; Olsson H; Hoglund M; Ullen A; Liedberg F
Article: BLADDER CANCER. 2022;8(1):71-80
Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen
Holmsten K; Omland LH; Als AB; Agerbaek M; Dohn LH; Lindberg H; Jensen NV; Carus A; Moe M; Hosseini A; Radkiewicz C; Pappot H; Ullen A
Article: EUROPEAN JOURNAL OF CANCER. 2020;127:173-182
Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)
Holmsten K; Jensen NV; Mouritsen LS; Jonsson E; Mellnert C; Agerbaek M; Nilsson C; Moe M; Carus A; Ofverholm E; Lahdenpera O; Brandberg Y; Johansson H; Hellstrom M; von der Maase H; Pappot H; Ullen A
Article: ONCOLOGIST. 2019;24(6):745-e213
Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
Shah C-H; Pappot H; Agerbaek M; Holmsten K; Jaderling F; Yachnin J; Gryback P; von der Maase H; Ullen A
Article: ONCOLOGY LETTERS. 2016;12(2):1293-1300
Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
Holmsten K; Dohn LH; Jensen NV; Shah C-H; Jaderling F; Pappot H; Ullen A
Article: MOLECULAR ONCOLOGY. 2016;10(5):719-734
Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma
Viktorsson K; Shah C-H; Juntti T; Haag P; Zielinska-Chomej K; Sierakowiak A; Holmsten K; Tu J; Spira J; Kanter L; Lewensohn R; Ullen A

All other publications

Letter: EUROPEAN UROLOGY. 2022;81(4):e92-e93
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
Sjodahl G; Abrahamsson J; Holmsten K; Bernardo C; Eriksson P; Kollberg P; Marzouka N-A; Hoglund M; Ullen A; Liedberg F
Thesis / dissertation: 2020
Improving chemotherapy in advanced urothelial cancer : real-world data studies and prospective clinical trials
Holmsten, Karin
Corrigendum: ONCOLOGY LETTERS. 2017;13(6):5035
Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis (vol 12, pg 1293, 2016)
Holmsten K; Dohn L; Jensen NV; Shah C-H; Jaderling F; Pappot H; Ullen A

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2024-2025

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2020

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI